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Contralateral occlusion is not a clinically
important reason for choosing carotid artery
stenting for patients with significant carotid artery
stenosis
Luke P. Brewster, MD, PhD, MA,a,b Robert Beaulieu, MD,c Karthik Kasirajan, MD,d
Matthew A. Corriere, MD, MS,a,e Joseph J. Ricotta II, MD,a Siddharth Patel, MD,a and
Thomas F. Dodson, MD,a Atlanta, Ga; Baltimore, Md; and Concord, Calif
Objective: Contralateral carotid artery occlusion by itself carries an increased risk of stroke. Carotid endarterectomy
(CEA) in the presence of contralateral carotid artery occlusion has high reported rates of perioperative morbidity and
mortality. Our objective was to determine if there is a clinical benefit to patients who receive carotid artery stenting (CAS)
compared to CEA in the presence of contralateral carotid artery occlusion.
Methods: We conducted a retrospective medical chart review over a 4.5-year institutional experience of persons with
contralateral carotid artery occlusion and ipsilateral carotid artery stenosis who underwent CAS or CEA. The main
outcome measures were 30-day cardiac, stroke, and mortality rate, and midterm mortality.
Results:Of a total of 713 patients treated for carotid artery stenosis during this time period, 57 had contralateral occlusion
(8%). Thirty-nine of these patients were treated with CAS, and 18 with CEA. The most common indications for CAS
were prior neck surgery (18), contralateral internal carotid occlusion (nine), and prior neck radiation (seven). The average
age was 70 8.5 for CEA and 66.7 9.3 for CAS (P .20). Both groups were predominantly men (CEA 12 of 18; CAS
28 of 39; P  .76), with similar prevalence of symptomatic lesions (CEA 8 of 18, CAS 20 of 39; P  .77). Two patients
died within 30 days in the CAS group (5%). No deaths occurred within 30 days in the CEA group (P .50); the mortality
rate for CAS and CEA combined was 3.5%. No perioperative strokes or myocardial infarction occurred in either group.
Two transient ischemic attacks occurred after CAS. At mean follow-up of 29.4  16 months (CEA) and 28  14.4
months (CAS; range, 1.5-48.5 months), seven deaths occurred in the CAS group and one in the CEA group (17.9% vs
5.5%; P  .40). There were two reinterventions in the CAS group for in-stent restenosis and there were no reoperations
in the CEA group.
Conclusions: Although CEA and CAS can both be performed with good perioperative results and acceptable midterm
mortality, the observed outcomes do not support use of contralateral carotid artery occlusion as a selection criterion for
CAS over CEA in the absence of other indications. ( J Vasc Surg 2012;56:1291-5.)
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cPatients with contralateral carotid artery occlusion have
a historically high stroke rate.1-3 The etiology is both
embolic and flow-related.4 Although some authors have
reported an association between contralateral occlusion
and increased morbidity/mortality after carotid endarter-
ectomy (CEA),5 others have reported excellent results with
CEA in these patients.6-8 Subgroup analysis of the North
American Symptomatic Carotid Endarterectomy Trial
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http://dx.doi.org/10.1016/j.jvs.2012.04.033NASCET) found that contralateral occlusion increased
he risk of stroke in patients undergoing ipsilateral carotid
ndarterectomy 2.5 times; however, CEA in this cohort
till reduced the risk of stroke compared to medical ther-
py.9 The Asymptomatic Carotid Artery Study (ACAS)
ubgroup analysis of patients with contralateral occlusion
77 medical; 86 surgical) found that these patients did not
enefit from CEA and may have an increased stroke risk.10
sing their cohort of 63 persons with contralateral occlu-
ion, AbuRahma et al11 found the natural history of these
atients after CEA to be relatively benign.
The addition of carotid artery stenting (CAS) as an
lternative mode of therapy adds more complexity to the
reatment paradigm for ipsilateral carotid artery stenosis
nd contralateral occlusion. Theoretic advantages of CAS
n patients with contralateral occlusions include decreased
schemia time, avoidance of shunt placement, and the abil-
ty to perform the procedure without sedation or anesthe-
ia. The group at Northwestern has recently published their
eries looking at CAS results in patients with and without
ontralateral occlusion; they found no significant increases
n periprocedural or long-term outcomes.12
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lication of results fromCarotid Revascularization Endarter-
ectomy versus Stenting Trial,13 and the current consider-
ation by the Center for Medicare and Medicaid Services to
expand reimbursement for CAS, characterization of patient
level anatomic and comorbidity factors that influence out-
comes has the potential to inform procedural selection.
Because contralateral carotid artery occlusion has been
designated a criterion for selecting CAS, our goal here was
to determine if CAS conferred a perioperative or midterm
clinical advantage over CEA in the management of ipsilat-
eral carotid artery disease in patients with contralateral
carotid artery occlusion.
METHODS
Institutional review board approval was obtained to
retrospectively review our institution’s multispecialty expe-
rience with CEA and CAS from February 2007 through
July 2011. Electronic medical records, procedural billing
codes, and clinical visit documentation were analyzed and
compiled into a database (Microsoft Access, Redmond,
Wash). Variables collected from the medical records in-
cluded age, gender, medical comorbidities including prior
myocardial infarction (MI) and stroke, preoperative anti-
platelet regimen, and history of any carotid revasculariza-
tion. Disease-specific characteristics included presence of
symptoms (as defined by NASCET criteria and physician
judgment), degree of stenosis, method of imaging modal-
ity, modality of therapy, and postoperative complications.
Mortality was determined by the medical record and use of
the Social Security Death Index.
The degree of stenosis in our study was preferentially
established by digital subtraction arteriograms, followed by
computed tomography arteriography, then magnetic reso-
nance arteriography. Ultrasound velocities were not used
to calculate percent stenoses as there are currently no
specific velocity criteria that are widely accepted for assess-
ment of stenosis in the presence of contralateral carotid
artery occlusion.14 For patients undergoing CAS, 33 of 39
patients (85%) had their percent stenosis defined by arte-
riogram. Six patients either did not have their percent
stenosis dictated or did not have their arteriograms avail-
able for review. For patients undergoing CEA, only 6 of 18
patients (33%) underwent arteriogram, two by magnetic
resonance arteriography, and 10 by computed tomography
arteriography.
Choice of therapy was determined by the individual
practitioner with some specialists providing both CAS and
CEA (4 of 10) to this patient population. These procedures
were all performed within a single institution by various
specialists (vascular surgeons, cardiologists, and neurosur-
geons) who treat carotid artery disease. Our group has
standardized its use of carotid duplex scan postprocedure.
Patients who undergo CAS have their first duplex scan at 1
month, whereas those with CEA have their first duplex scan
at 6 months. Surveillance duplex scan studies then occur
every 6 to 12 months for both groups. wPrimary outcomemeasure was a combined end point of
troke, MI (troponin I or electrocardiogram criteria), or
eath in the 30 days after intervention. Secondary out-
omes included transient ischemic attack (TIA), brady-
ardic/hypotensive sequelae, secondary procedures, inten-
ive care unit (ICU) stay, length of hospitalization, and late
eath (30 days). Patient cohorts were grouped by CAS
nd CEA. Planned comparisons were analyzed between
EA and CAS and were analyzed using two-tailed Fisher
xact and t-tests, as appropriate, with a P value of .05
onsidered significant.
ESULTS
Of a total of 713 patients treated for carotid artery
tenosis during this time period, 57 had contralateral oc-
lusion (8.0%). Thirty-nine of these patients were treated
ith CAS, and 18 with CEA. Themost common indication
or CAS were prior neck surgery (18), contralateral carotid
cclusion alone (nine), and prior neck radiation (seven). Of
he remaining patients, three underwent CAS for high
edical risk, one for age 80, and one for a high carotid
ifurcation. The two groups were similar with regard to the
ean age, gender distribution, presence of symptomatic
esions, and mean percent stenosis. Also, patient comor-
idities were also similar between groups with the excep-
ion that significantly more patients with prior CEA under-
ent CAS (Table).
Two patients died within 30 days in the CAS group
5%). One patient died 3 weeks after CAS from respiratory
ailure precipitated by a seizure remote from discharge. In
his patient, the computed tomography scan of the head
id not identify a stroke or hemorrhage. The second death
esulted from complications of a retroperitoneal hematoma
n the side accessed for the CAS. No deaths occurred
able. Patient characteristics before undergoing carotid
herapy
CEA %
(n  18)
CAS %
(n  39) P value
ge 70  8.5 66.7  9.3 .20
ales 12/18 28/39 .76
ymptomatic patients 8/18 20/39 .77
ercent stenosis 78.9  10.6 82.3  13.0 .33
moker 27.8 (5) 35.9 (14) .38
rior CAS (either side) 0 (0) 10.2 (4) .21
rior neck surgery 5.6 (1) 46.1 (18) .002
ypertension 100 (18) 82.1 (32) .06
rior stroke (either side) 33.3 (6) 35.9 (14) .55
IA (either side) 27.8 (5) 41.0 (16) .25
iabetes 27.8 (5) 41.0 (16) .25
I 11.2 (2) 15.4 (6) .51
SRD 0 (0) 5.1 (2) .46
OPD 11.1 (2) 25.6 (10) .19
LD 72.2 (13) 69.2 (27) .55
AS,Carotid artery stenting;CEA, carotid endarterectomy;COPD, chronic
bstructive pulmonary disease; ESRD, end-stage renal disease;HLD, hyper-
ipidemia; MI, myocardial infarction; TIA, transient ischemic attack.ithin 30 days in the CEA group (P  .49). No perioper-
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Volume 56, Number 5 Brewster et al 1293ative strokes or MIs were identified in either group. Two
transient ischemic attacks occurred after CAS, both in
symptomatic patients. One was in the ipsilateral distribu-
tion and one in the contralateral distribution (P  .49).
Neither patient was further evaluated by neurology acutely,
but one was followed by the neurologist involved in the
preinterventional care in an outpatient setting.
At mean follow-up of 29.4  16 months (CEA) and
28  14.4 months (CAS; range, 1.5-48.5 months), five
additional deaths were identified in the CAS group and one
death in the CEA group (5 of 37  13.5% vs 5.5%, not
significant). All six late deaths were in patients with hyper-
tension, five of six late deaths were in patients with chronic
obstructive pulmonary disease, three of six patients had
diabetes, and two of six patients had prior strokes. The
average length of time between CAS and death was 16.6
16.3 months (range, 3 days-38 months) with only two
patients dying more than 2 years from their procedure;
excluding 30-day deaths, the average time from procedure
to death was 23.1  14.7 months. The late death in the
CEA group was 42 months after the operation. There were
no reoperations in the CEA group and two reinterventions
in the CAS group for in-stent stenosis (P  .49); one of
these patients had prior neck radiation. ICU utilization
was similar between the two groups with five patients
admitted to the ICU after CEA and seven after CAS
(P .37). However, the CAS group had three ICU admis-
sions for blood pressure support whereas the CEA group
had none. The average lengths of stay were significantly
longer for the CEA group over the CAS group (3.3  2.5
days vs 2.0  1.5 days; P  .02).
Only one of 39 patients who underwent CAS was not
on antiplatelet therapy (due to gastrointestinal bleeding).
One of the patients who died within 30 days was on dual
antiplatelet therapy and died during a late presentation of a
retroperitoneal hematoma. Four of 18 patients who under-
went CEA did not have antiplatelet therapy, but three of
these were anticoagulated with Coumadin for other con-
siderations. Eight of 16 patients who underwent CEA were
on a statin preoperatively (twomedical records did not have
this information), and 21 of 37 patients who underwent
CAS were on a statin (3 medical records did not have this
information); P  .39. Thirty-one of 39 patients who
underwent CAS and 17 of 18 patients who underwent CEA
were performed by members of our vascular surgery divi-
sion. The majority of CAS was performed with distal pro-
tection devices, but six were completed as part of the
Embolic Protection with Flow Reversal Trial. Here, one
person did not tolerate flow reversal, but this procedure was
completed with an embolic protection device. One person
had the CAS procedure terminated as the patient could no
longer tolerate it due to claustrophobia. This person un-
derwent an uneventful CEA in the same hospitalization.
No CEAs were aborted. Only two patients had their CEA
performed without the use of general anesthesia. Routine
shunting and patch closure was performed for the CEA
with three exceptions, all in patients under general anesthe-
sia. The first patient had electroencephalogram tracings and arimary closure; the second patient was monitored by and
ad no changes in cerebral oximetry; the third patient had
shunt placed but it was removed due to concern of shunt
alfunction. This patient was monitored by and also had
o changes in cerebral oximetry throughout the operation.
ISCUSSION
This study does not support the superiority of CAS over
EA in the presence of contralateral carotid artery occlu-
ion. Although there were no perioperative strokes in either
roup, the 5%mortality rate in the CAS group suggests that
troke is not necessarily the sole source of early mortality in
atients undergoing CAS. Further, the average time to
eath after CAS was relatively short, suggesting that patient
election with regard to expected lifespan can be improved.
ositively, CAS was associated with a shorter length of stay.
here was a zero stroke and death rate in our CEA group,
lbeit with small numbers of CEA performed. ICU admis-
ion and compliance with antiplatelet therapy were not
ignificantly different between treatment groups.
The limitations of this study include the absence of
focused preoperative and postoperative neurologic ex-
mination by a neurologist, resulting in possible under-
epresentation of neurologic events, and the absence of
creening troponin levels and electrocardiogram tests,
hich may have resulted in underreporting of non-Q wave
Is. Further, althoughwe report no periprocedural strokes
nd a combined mortality rate of 3.5%, the numbers are
nsufficient to establish that contralateral occlusion is not
elated to an increase in periprocedural morbidity and
ortality. In fact, there are a number of larger multiple
nstitutional studies published recently that suggest it
s.15,16 Finally, because this is not a randomized study,
here may have been a predilection to have sicker patients in
he CAS group, thus biasing the data toward CEA. How-
ver, we believe that this effect, if present, is small given the
imilarities of comorbidities and the fact that only 3 of 39
atients who underwent CAS were placed in this group for
edical morbidity reasons. Given the unique benefits/risks
f both procedures and the prevalence of contralateral
cclusion in8% of patients undergoing carotid therapy, a
andomized trial to address this issue definitively is unlikely.
hus, institutional experiences like this are necessary to assist
linicians in making these decisions with their patients.
Importantly, although these patients were cared for in a
igh-volume center by a number of practitioners from
arious specialties, the majority of procedures were per-
ormed by vascular surgeons. Two of the 10 CAS practitio-
ers performed more than 12 CAS procedures annually.
till, practitioners had a low TIA rate, null stroke rate, and
cceptable perioperative mortality.
Longer term analysis of this database may be able to
rovide better prognostic information on the average
ength of patient survival after undergoing carotid therapy.
his would be helpful to better identify populations with
reater and lesser likely benefit from carotid therapy. Be-
ause the beneficial role of carotid therapy in patients with
symptomatic carotid artery stenosis and contralateral ca-
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recommends therapy in these patients when their stenosis is
80%, we have initiated a collaboration with our neurology
colleagues to examine the stroke/death rate of patients
with contralateral occlusion who are treated medically or
with an intervention. Further, aggressive blood pressure
management and proper medical therapy is essential to
the care of these patients as demonstrated recently by the
surprisingly good results of medical therapy in both the
CarotidOcclusion Surgery Study17 and Stenting vs Aggres-
sive Medical Management for Preventing Recurrent Stroke
in Intracranial Stenosis18 trials. Improving the initiation
and compliance of optimal medical therapy, including sta-
tin, antiplatelets, and proper antihypertensive medications,
will likely be critical to not only limiting procedural mor-
bidity andmortality but also in maximizing survival of these
patients after successful carotid artery therapy.
CONCLUSIONS
CAS was not associated with improved outcomes com-
pared to CEA in patients with contralateral occlusion. We
do not think that contralateral occlusion is a clinically
important reason for choosing CAS over CEA, but the
majority of patients (30 of 39) undergoing CAS with
contralateral occlusion had other reasons for choosing
CAS, which limits the impact of these findings. The role of
carotid artery therapy in asymptomatic patients with con-
tralateral occlusion remains undefined in the current era.
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Dr Charles B. Ross (Louisville, Ky). This report from the
Emory University group, excellently presented by Dr Brewster,
seeks to answer whether or not contralateral carotid occlusion
(CCO) is an important reason to prefer CAS over CEA in patients
requiring invasive carotid intervention. I appreciated receipt of the
manuscript well before the meeting.
In this study, 39 patients were treated by CAS, and more than
one half of these had “hostile necks.” There were 18 cases treated
by CEA, and almost all of these operations were performed withomatic status or traditional risk factors. No perioperative strokes
r MIs were observed in either group, but two TIAs were noted
fter CAS. One death from retroperitoneal hematoma occurred
fter CAS, and one death occurred shortly after discharge due to a
eizure, apparently not related to hyperperfusion.
Based on the data, it is concluded that CCO is not an impor-
ant reason to choose CAS over CEA. I have a few questions and a
omment.
Six deaths were observed in the CAS group over a follow-up of
nly 28  15 months. In my own practice, I have encountered
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Volume 56, Number 5 Brewster et al 1295referrals for CAS in patients who have limited prognoses. I have
said “no” to CAS and managed these patients medically. In retro-
spect, would medical management have been more appropriate for
some of the patients treated in your CAS group?
What was the timing and presumed cause of the TIAs in the
CAS group? Were there technical or other management issues? We
treat all patients who undergo CAS with dual antiplatelet therapy,
but one problem we have recently encountered has been resistance
to clopidogrel. We now routinely check platelet function assays
before taking our patients to the laboratory for CAS.
Given that the presence of a “hostile neck” is considered by
many to be one of the more solid reasons to perform CAS as
opposed to CEA, would you manage these patients differently
now? More importantly, which patients/indications does your
group feel are appropriate candidates for CAS? What is the Emory
practice now?
Finally, I have concerns that your numbers are too small to
support the conclusion made by this article. This report, like many
other individual reports from busy carotid practices and meta-
analyses of the same, shows excellent surgical results in patients
with CCO. Yet, two important publications within the past year
detailing large numbers of patients, one from the Vascunet Euro-
pean Group and the other from the New England Vascular Study
Group, have shown that CCO increases the risk of perioperative
stroke/death after CEA by a factor of approximately two. This has
not been true for CAS. So, proponents of CAS for carotid inter-
vention in the setting of CCO still have a strong argument.
I thank the Society for the opportunity to initiate this discus-
sion.
Dr Luke P. Brewster. Thank you, Dr Ross. Thank you also for
meeting with me to discuss the article. I agree completely that the
stratification of patients with regard to lifespan is critical to the proper
application of carotid artery therapy. I do not think anything has
changed since NASCET or ACAS to suggest benefits in persons not
expected to live 2 or 5 years. In our series, one of the late deaths had
a home oxygen requirement before therapy. Chronic obstructive
pulmonary disease is another predictor of decreased lifespan, but I do
not think that the diagnosis of chronic obstructive pulmonary disease
is elegant enough to stratify patients. Pulmonary function tests, forced
expiratory volume in 1 second or diffusion capacity for carbon mon-
oxide in particular, may be helpful, particularly in asymptomatic
patients. Regardless, I think expected lifespan after the procedure and
expected outcome of the procedure need to be examined together. If
I remember correctly, Dr Goodney’s group looked at the application
of carotid therapy in the Medicare population and found many
surgeries were performed in persons that were unlikely to live long
enough to benefit. The TIAs were both during the procedure and
m
tere self-limited that one occurred during the ballooning and one
ccurred after retrieving the sheath into the aorta. Presumably, I
ould think that these would be embolic in nature. We do not check
latelet resistance, but I like your approach. Certainly adequate acti-
ated clotting time levels are critical to carotid stenting. Platelet
esistance is a real problem but the most recent meta-analysis looking
t Plavix in the context of specific mutations found a null effect. Our
ndications forCAS are both anatomic andmedical. I think the caveats
re persons with valvular disease. We have had a couple of these
atients decompensate after bradycardia or hypotension; they do not
ave the capacity to tolerate this complication. Now I would add that
ontralateral occlusion is not an indication for carotid stenting.
I would not handle patients that have contralateral occlusion
nd other indications for carotid stenting differently because we
id not find carotid stenting harmful in this population; rather it
rovided no benefit over endarterectomy. Dr Ross, you brought
p two recent articles – one I knew well and one I learned from
ou. The former was from the New England Study Group, and the
atter looked at results out of Europe’s Vascunet Group. Vascunet
ad about 75% symptomatic patients and they studied people up
ntil, I think, 2009 and similarly with the New England Study
roup; both groups looked exclusively at endarterectomy. The
ew England Study Group did look at the benefit of shunt by
eople who routinely placed them vs those that did not. I think
hat the major finding here was that surgeons who shunt routinely
o better shunting patients with contralateral occlusion. We fully
upport shunting these patients. Vascunet found higher stroke
ates in patients with contralateral occlusion. Our study is not
owered to refute theirs (1700 patients). With regards to the
idterm mortality we identified, Dr Eskadari, who is here along
ith one of my colleagues from General Surgery training, Mark
eldahl, recently published Northwestern’s experience looking at
AS in patients with contralateral occlusion. They found a 25%
ortality rate at a mean follow-up of 4 years. Our rate here is
imilar. Being that the peak age for carotid therapy is about 70
ears, and the average age people are now living is to the mid 80s,
think long-term restenosis is going to be a critical parameter to
ollow. I completely support Dr Ross’ recent article calling upon
etter documentation and reporting of carotid stents over time.
his is a long-term goal of Emory’s database, trying to find out
ow patients do after carotid therapy over time. In fact, what first
ot me interested in this question was the article from Bill Baker at
oyola that showed there was questionable benefit of CEA in
atients with contralateral occlusion in the ACAS trial. In sum-
ary, future reporting of outcomes will be well served, including
idterm or later outcomes, and I think we will be able as a Society
o address with Vascular Quality Initiative.
